
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia is poised for continued success as Yutrepia's sales and potential for expansion and new uses are strong, and the company's innovative technology and potential improvements to their product have positioned them well in the market.
Bears say
Liquidia is facing increasing competition in the inhaled prostacyclin market and their main product YUTREPIA has shown only marginal cough reduction compared to other DPIs, despite repeat prescribing behavior. They are also heavily relying on the success of their investigational product L606, which may face difficulties in the market as newer, more convenient options become available. Additionally, the outcome of ongoing patent litigation poses a significant risk to the company's success and continued growth.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares